# Infectious Diseases (travel medicine) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Pierre Le Moyne d'Iberville (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET014-SYN-TD
- Date: 1705-03-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Jean-Baptiste Okonkwo-Hale, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Marguerite Delacroix-Boateng, MD

## Reason for consultation

Three episodes of fever with shaking chills and sweats in two years, each beginning months after naval service in malaria-endemic areas, the first called malaria abroad and treated with chloroquine alone, in a 43-year-old naval commander who is afebrile today. Please establish whether these are malaria relapses, advise on antirelapse treatment, and plan his pre-travel care for a deployment to French Guiana and the French Antilles expected early next year. **S**

## History

Mr. Le Moyne d'Iberville, a 43-year-old naval commander, is seen at the request of Dr. Delacroix-Boateng for recurrent fevers. Over two years he has had three attacks, each about a week of fever with shaking chills every other day, drenching sweats and headache, each beginning months after he left a posting on the Caribbean coast of Central America or the Gulf of Mexico. The first attack was diagnosed as malaria on a smear abroad, species not recorded, and all three were treated with chloroquine alone; he has never taken primaquine or tafenoquine. The last attack ended eight weeks ago and he has had no fever since. He takes no medicines and has no allergies. He is preparing a squadron for a deployment to the French Antilles and French Guiana early next year, with months ashore and possible inland river work. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; temperature 36.6 C, blood pressure 122/76, pulse 68 |
| Eyes | Mild conjunctival pallor; no jaundice |
| Abdomen | Spleen tip not palpable; liver not enlarged |
| Skin | No rash |

BP 122/76 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 68.6 kg; BMI 22.4 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Delacroix-Boateng's intake note and tests: thick and thin smears and rapid antigen test negative; Plasmodium species PCR from the intake sample, reported this week, detected P. vivax DNA; hemoglobin 13.0 g/dL, platelets 141 x10^3/uL, white cells 5.6 x10^3/uL, bilirubin 1.1 mg/dL, ALT 34 U/L, AST 29 U/L, creatinine 0.98 mg/dL, glucose 92 mg/dL; quantitative G6PD activity 11.8 U/g Hb, within the laboratory's normal range. 

## Assessment

1. **Relapsing Plasmodium vivax malaria** (B51.9). Attacks months after leaving areas where P. vivax predominates, after blood-stage treatment alone, with P. vivax DNA detected between attacks, are relapses from dormant liver stages (hypnozoites). The PCR detects parasites below the threshold of the smear. Mildly low hemoglobin and platelets fit recent attacks. No further diagnostic test is needed. Central American P. vivax is chloroquine-sensitive. With a normal quantitative G6PD, primaquine 30 mg base daily for 14 days is appropriate; at 68 kg that dose meets the total recommended dose. **S**
2. **Pre-travel care for French Guiana and the French Antilles** (Z71.84). French Guiana requires proof of yellow fever vaccination from all arriving travelers, and CDC recommends it; one dose gives long-lasting protection. Hepatitis A, hepatitis B (if not immune) and typhoid vaccines are recommended for a long stay. Malaria is transmitted in parts of French Guiana, mostly P. vivax with some P. falciparum and chloroquine resistance, so chloroquine is not suitable for prophylaxis there. Dengue, chikungunya and rickettsial infections including typhus are prevented by vector avoidance; no dengue vaccine is recommended for travelers. **S**

## Recommendations

1. Chloroquine 1,000 mg salt now, then 500 mg at 6, 24 and 48 hours, for the blood stage.
2. Primaquine 30 mg base daily with food for 14 days for radical cure, starting today; stop and seek care for dark urine, breathlessness or blue lips.
3. Blood smear and PCR about a week after the last primaquine dose, with a blood count and bilirubin; then no routine tests, but a smear the same day for any fever.
4. Pre-travel vaccines at least a month before departure: yellow fever with the international certificate, hepatitis A, typhoid Vi, and hepatitis B if the screening panel shows he is not immune; influenza in the autumn.
5. Atovaquone-proguanil chemoprophylaxis for the malaria areas, with primaquine terminal prophylaxis for 14 days after leaving them because of prolonged P. vivax exposure.
6. Repellent, permethrin-treated clothing, bed nets and screened quarters against mosquitoes, fleas, lice and mites; food and water precautions with standby azithromycin for severe travelers' diarrhea.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Delacroix-Boateng, who saw him the same day. The diagnosis and plan were explained to Mr. Le Moyne d'Iberville, who agreed and took the first chloroquine dose in clinic. **S**

## Follow-up

Infectious diseases review on request or for any fever; primary care review in four weeks and pre-travel vaccines in the summer. **S**

## Guideline basis

- Treatment of Uncomplicated Malaria (clinical guidance) (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026), Centers for Disease Control and Prevention
- CDC Yellow Book: Health Information for International Travel, 2026 edition. Yellow Fever (2026), Centers for Disease Control and Prevention
- French Guiana (France): travel health destination page (yellow fever and malaria information updated April 2025) (2026), Centers for Disease Control and Prevention
- The practice of travel medicine: guidelines by the Infectious Diseases Society of America (Hill DR, et al. Clin Infect Dis 2006;43(12):1499-1539) (2006), Infectious Diseases Society of America
